A型流感病毒诱导细胞炎症反应的研究进展

doi:10.11843/j.issn.0366-6964.2024.02.007

摘要/Abstract

摘要： A型流感病毒(influenza A virus, IAV)是一种呼吸道病原体,可诱导宿主发生炎症反应,促进炎症细胞聚集,释放大量趋化因子、细胞因子以及转录因子等炎症因子,引起宿主过度炎症,导致细胞死亡和组织损伤。IAV编码的多种蛋白质可通过不同的机制参与宿主炎症反应,大大增加IAV感染的发病率和死亡率。越来越多的研究表明,免疫调节策略可以在不影响宿主抵抗感染的情况下改善疾病预后。本文综述了IAV引发炎症反应的最新进展,以便为临床治疗IAV提供新思路。

关键词: A型流感病毒, 炎症, 免疫调节治疗

Abstract: Influenza A virus (IAV) is a respiratory pathogen that can induce inflammatory response in the host. It can induce host inflammatory response and promote the aggregation of inflammatory cells. A large number of inflammatory factors such as chemokines, cytokines, and transcription factors are released, causing excessive host inflammation and eventually leading to cell death and tissue damage. Various proteins encoded by IAV can participate in host inflammatory response through different mechanisms, greatly increasing the morbidity and mortality caused by IAV. A growing body of research suggests that immunomodulatory strategies can improve disease prognosis without affecting the host's resistance to infection. In order to provide new ideas for clinical treatment of IAV infection, this paper reviews the recent progress of IAV-induced inflammatory response.

Key words: influenza A virus, inflammation, immunoregulatory therapy

中图分类号:

S855.3

高欣, 孙怡朋. A型流感病毒诱导细胞炎症反应的研究进展[J]. 畜牧兽医学报, 2024, 55(2): 481-490.

GAO Xin, SUN Yipeng. Research Progress of Cell Inflammation Induced by Influenza A Virus[J]. Acta Veterinaria et Zootechnica Sinica, 2024, 55(2): 481-490.

参考文献

[1] KLOMP M, GHOSH S, MOHAMMED S, et al. From virus to inflammation, how influenza promotes lung damage[J]. J Leukoc Biol, 2021, 110(1):115-122.
[2] BOONSTRA S, BLIJLEVEN J S, ROOS W H, et al. Hemagglutinin-mediated membrane fusion:a biophysical perspective[J]. Annu Rev Biophys, 2018, 47:153-173.
[3] NEWTON A H, CARDANI A, BRACIALE T J. The host immune response in respiratory virus infection:balancing virus clearance and immunopathology[J]. Semin Immunopathol, 2016, 38(4):471-482.
[4] HEROLD S, BECKER C, RIDGE K M, et al. Influenza virus-induced lung injury:pathogenesis and implications for treatment[J]. Eur Respir J, 2015, 45(5):1463-1478.
[5] WU N C, WILSON I A. Influenza hemagglutinin structures and antibody recognition[J]. Cold Spring Harb Perspect Med, 2020, 10(8):a038778.
[6] KALIL A C, THOMAS P G. Influenza virus-related critical illness:pathophysiology and epidemiology[J]. Crit Care, 2019, 23(1):258.
[7] HUGHES C E, NIBBS R J B. A guide to chemokines and their receptors[J]. FEBS J, 2018, 285(16):2944-2971.
[8] HUO C Y, XIAO K, ZHANG S P, et al. H5N1 influenza a virus replicates productively in pancreatic cells and induces apoptosis and pro-inflammatory cytokine response[J]. Front Cell Infect Microbiol, 2018, 8:386.
[9] MACLEAN A J, RICHMOND N, KONEVA L, et al. Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites[J]. Immunity, 2022, 55(4):718-733. e8.
[10] GURCZYNSKI S J, NATHANI N, WARHEIT-NIEMI H I, et al. CCR2 mediates increased susceptibility to post-H1N1 bacterial pneumonia by limiting dendritic cell induction of IL-17[J]. Mucosal Immunol, 2019, 12(2):518-530.
[11] TAVARES L P, GARCIA C C, MACHADO M G, et al. CXCR1/2 antagonism is protective during influenza and post-influenza pneumococcal infection[J]. Front Immunol, 2017, 8:1799.
[12] LIU S, LIU J Q, YANG X, et al. Cis-acting lnc-Cxcl2 restrains neutrophil-mediated lung inflammation by inhibiting epithelial cell CXCL2 expression in virus infection[J]. Proc Natl Acad Sci U S A, 2021, 118(41):e2108276118.
[13] MORRIS G, BORTOLASCI C C, PURI B K, et al. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?[J]. Cytokine, 2021, 144:155593.
[14] SZRETTER K J, GANGAPPA S, LU X, et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice[J]. J Virol, 2007, 81(6):2736-2744.
[15] CROTTA S, DAVIDSON S, MAHLAKOIV T, et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia[J]. PLoS Pathog, 2013, 9(11):e1003773.
[16] ALAGARASU K, KAUSHAL H, SHINDE P, et al. TNFA and IL10 polymorphisms and IL-6 and IL-10 levels influence disease severity in influenza A(H1N1)pdm09 virus infected patients[J]. Genes, 2021, 12(12):1914.
[17] YAMAYA M, NADINE L K, OTA C, et al. Magnitude of influenza virus replication and cell damage is associated with interleukin-6 production in primary cultures of human tracheal epithelium[J]. Respir Physiol Neurobiol, 2014, 202:16-23.
[18] WANG X H, MA K Y, CHEN M, et al. IL-17A promotes pulmonary B-1a cell differentiation via induction of blimp-1 expression during influenza virus infection[J]. PLoS Pathog, 2016, 12(1):e1005367.
[19] CROWE C R, CHEN K, POCIASK D A, et al. Critical role of IL-17RA in immunopathology of influenza infection[J]. J Immunol, 2009, 183(8):5301-5310.
[20] BERMEJO-MARTIN J F, ORTIZ DE LEJARAZU R, PUMAROLA T, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza[J]. Crit Care, 2009, 13(6):R201.
[21] DAI X X, ZHANG L S, HONG T. Host cellular signaling induced by influenza virus[J]. Sci China Life Sci, 2011, 54(1):68-74.
[22] SCHMOLKE M, VIEMANN D, ROTH J, et al. Essential impact of NF-κB signaling on the H5N1 influenza A virus-induced transcriptome[J]. J Immunol, 2009, 183(8):5180-5189.
[23] BERNASCONI D, AMICI C, LA FRAZIA S, et al. The IκB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells[J]. J Biol Chem, 2005, 280(25):24127-24134.
[24] WAN P, ZHANG S M, RUAN Z H, et al. AP-1 signaling pathway promotes pro-IL-1β transcription to facilitate NLRP3 inflammasome activation upon influenza A virus infection[J]. Virulence, 2022, 13(1):502-513.
[25] ZHAO M Z, GUO X, SUN B, et al. HA of H1N1 enhanced the expression of ICAM-1 and IL-6 in HUVECs and pathological injury in the lungs in mice[J]. Gene, 2021, 801:145854.
[26] FORERO A, TISONCIK-GO J, WATANABE T, et al. The 1918 influenza virus PB2 protein enhances virulence through the disruption of inflammatory and wnt-mediated signaling in mice[J]. J Virol, 2015, 90(5):2240-2253.
[27] KURIAKOSE T, MAN S M, MALIREDDI R K S, et al. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways[J]. Sci Immunol, 2016, 1(2):aag2045.
[28] KIM C U, JEONG Y J, LEE P, et al. Extracellular nucleoprotein exacerbates influenza virus pathogenesis by activating Toll-like receptor 4 and the NLRP3 inflammasome[J]. Cell Mol Immunol, 2022, 19(6):715-725.
[29] CHOUDHURY S M, MA X S, ABDULLAH S W, et al. Activation and inhibition of the NLRP3 inflammasome by RNA viruses[J]. J Inflamm Res, 2021, 14:1145-1163.
[30] GABA A, XU F, LU Y, et al. The NS1 protein of influenza A virus participates in necroptosis by interacting with MLKL and increasing its oligomerization and membrane translocation[J]. J Virol, 2019, 93(2):e01835-18.
[31] PINAR A, DOWLING J K, BITTO N J, et al. PB1-F2 peptide derived from avian influenza A virus H7N9 induces inflammation via activation of the NLRP3 inflammasome[J]. J Biol Chem, 2017, 292(3):826-836.
[32] NIETO A, VASILIJEVIC J, SANTOS N B, et al. Mutation S110L of H1N1 influenza virus hemagglutinin:a potent determinant of attenuation in the mouse model[J]. Front Immunol, 2019, 10:132.
[33] CHAMBERLAIN N, KORWIN-MIHAVICS B R, NAKADA E M, et al. Lung epithelial protein disulfide isomerase A3 (PDIA3) plays an important role in influenza infection, inflammation, and airway mechanics[J]. Redox Biol, 2019, 22:101129.
[34] YU M, ZHANG K Z, QI W B, et al. Expression pattern of NLRP3 and its related cytokines in the lung and brain of avian influenza virus H9N2 infected BALB/c mice[J]. Virol J, 2014, 11(1):229.
[35] DESROCHERS B L, CHEN R E, GOUNDER A P, et al. Residues in the PB2 and PA genes contribute to the pathogenicity of avian H7N3 influenza A virus in DBA/2 mice[J]. Virology, 2016, 494:89-99.
[36] SHRIVASTAVA G, LEÓN-JUÁREZ M, GARCÍA-CORDERO J, et al. Inflammasomes and its importance in viral infections[J]. Immunol Res, 2016, 64(5-6):1101-1117.
[37] TAO P, NING Z Y, ZHOU P, et al. H3N2 canine influenza virus NS1 protein inhibits canine NLRP3 inflammasome activation[J]. Vet Immunol Immunopathol, 2022, 252:110483.
[38] CLARK A M, NOGALES A, MARTINEZ-SOBRIDO L, et al. Functional evolution of influenza virus NS1 protein in currently circulating human 2009 pandemic H1N1 viruses[J]. J Virol, 2017, 91(17):e00721-17.
[39] LEYMARIEO, MEYER L, TAFFOREAU L, et al. Influenza virus protein PB1-F2 interacts with CALCOCO2 (NDP52) to modulate innate immune response[J]. J Gen Virol, 2017, 98:1196-1208.
[40] MIODEK A, VIDIC J, SAURIAT-DORIZON H, et al. Electrochemical detection of the oligomerization of PB1-F2 influenza A virus protein in infected cells[J]. Anal Chem, 2014, 86(18):9098-9105.
[41] CHEVALIER C, LEYMARIE O, SEDANO L, et al. PB1-F2 amyloid-like fibers correlate with proinflammatory signaling and respiratory distress in influenza-infected mice[J]. J Biol Chem, 2021, 297(1):100885.
[42] FEDSON D S. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents:why they are needed and how they might work[J]. Influenza Other Respir Viruses, 2009, 3(4):129-142.
[43] KAISER L, FRITZ R S, STRAUS S E, et al. Symptom pathogenesis during acute influenza:interleukin-6 and other cytokine responses[J]. J Med Virol, 2001, 64(3):262-268.
[44] TAVARES L P, TEIXEIRA M M, GARCIA C C. The inflammatory response triggered by Influenza virus:a two edged sword[J]. Inflamm Res, 2017, 66(4):283-302.
[45] ATAMNA A, BABITCH T, BRACHA M, et al. Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(12):2341-2348.
[46] ZHENG B J, CHAN K W, LIN Y P, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus[J]. Proc Natl Acad Sci U S A, 2008, 105(23):8091-8096.
[47] ZHANG H B, ALFORD T, LIU S Q, et al. Influenza virus causes lung immunopathology through down-regulating PPARγ activity in macrophages[J]. Front Immunol, 2022, 13:958801.
[48] MORITA M, KUBA K, ICHIKAWA A, et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza[J]. Cell, 2013, 153(1):112-125.
[49] GARCIA C C, RUSSO R C, GUABIRABA R, et al. Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice[J]. PLoS Pathog, 2010, 6(11):e1001171.
[50] CHEN M F, WENG K F, HUANG S Y, et al. Pretreatment with a heat-killed probiotic modulates monocyte chemoattractant protein-1 and reduces the pathogenicity of influenza and enterovirus 71 infections[J]. Mucosal Immunol, 2017, 10(1):215-227.
[51] ZHAO J N, ZHU M Y, JIANG H, et al. RETRACTED ARTICLE:combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug:a potential therapy against pathogenic influenza virus[J]. Sci Rep, 2019, 9(1):5272.
[52] SUN S H, ZHAO G Y, LIU C F, et al. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys[J]. Clin Infect Dis, 2015, 60(4):586-595.
[53] SATO K, SUGA M, AKAIKE T, et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice[J]. Am J Respir Crit Care Med, 1998, 157(3 Pt 1):853-857.
[54] KARLSTRÖM A, BOYD K L, ENGLISH B K, et al. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza[J]. J Infect Dis, 2009, 199(3):311-319.
[55] HIGASHI F, KUBO H, YASUDA H, et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza[J]. Respir Investig, 2014, 52(5):302-309.
[56] SHARMA G, CHAMPALAL SHARMA D, HWEI FEN L, et al. Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor[J]. Emerg Microbes Infect, 2013, 2(1):e54.
[57] OOSTWOUD L C, GUNASINGHE P, SEOW H J, et al. Apocynin and ebselen reduce influenza A virus-induced lung inflammation in cigarette smoke-exposed mice[J]. Sci Rep, 2016, 6(1):20983.
[58] SHI X L, SHI Z H, HUANG H, et al. PEGylated human catalase elicits potent therapeutic effects on H1N1 influenza-induced pneumonia in mice[J]. Appl Microbiol Biotechnol, 2013, 97(23):10025-10033.
[59] ZHANG R H, LI C H, WANG C L, et al. N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury[J]. Int Immunopharmacol, 2014, 22(1):1-8.
[60] AEFFNER F, WOODS P S, DAVIS I C. Activation of A₁-adenosine receptors promotes leukocyte recruitment to the lung and attenuates acute lung injury in mice infected with influenza A/WSN/33 (H1N1) virus[J]. J Virol, 2014, 88(17):10214-10227.
[61] PLANZ O. Development of cellular signaling pathway inhibitors as new antivirals against influenza[J]. Antiviral Res, 2013, 98(3):457-468.
[62] MEHRBOD P, OMAR A R, HAIR-BEJO M, et al. Mechanisms of action and efficacy of statins against influenza[J]. Biomed Res Int, 2014, 2014:872370.
[63] LIU Z Y, GUO Z M, WANG G L, et al. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice[J]. Eur J Pharm Sci, 2009, 38(3):215-223.
[LL] [64] MEHRBOD P, HAIR-BEJO M, TENGKU IBRAHIM T A, et al. Simvastatin modulates cellular components in influenza A virus-infected cells[J]. Int J Mol Med, 2014, 34(1):61-73.
[65] DARWISH I, MUBAREKA S, LILES W C. Immunomodulatory therapy for severe influenza[J]. Expert Rev Anti-Infect Ther, 2011, 9(7):807-822.
[66] LAUDER S N, TAYLOR P R, CLARK S R, et al. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity[J]. Thorax, 2011, 66(5):368-374.
[67] BASSAGANYA-RIERA J, SONG R, ROBERTS P C, et al. PPAR-γ activation as an anti-inflammatory therapy for respiratory virus infections[J]. Viral Immunol, 2010, 23(4):343-352.
[68] BUDD A, ALLEVA L, ALSHARIFI M, et al. Increased survival after gemfibrozil treatment of severe mouse influenza[J]. Antimicrob Agents Chemother, 2007, 51(8):2965-2968.
[69] RUSSELL C D, SCHWARZE J. The role of pro-resolution lipid mediators in infectious disease[J]. Immunology, 2014, 141(2):166-173.
[70] LIN K L, SUZUKI Y, NAKANO H, et al. CCR2⁺ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality[J]. J Immunol, 2008, 180(4):2562-2572.
[71] IWASAKI A, MEDZHITOV R. A new shield for a cytokine storm[J]. Cell, 2011, 146(6):861-862.